Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder with no approved treatments that slow or stop disease progression.
The collaboration brings together open-science drug discovery with AI-driven molecular design, synthesis, and biological testing in a transparent design–make–test–analyze (DMTA) workflow. Variational AI applies its Enki™ generative AI platform to design new PRMT6 inhibitor candidates, while project data generated through the program will be shared openly in keeping with Agora’s open science model.
What Enamine adds to the collaboration?
Enamine strengthens a critical part of the discovery cycle: the ability to move quickly from computational design to real compounds that can be synthesized and tested.
In this program, Enki’s molecular generation is constrained to Enamine REAL Space and extended xREAL chemical space, helping ensure that proposed designs are grounded in synthetically accessible chemistry from the start. That makes it easier to translate promising ideas into compounds, support rapid iteration, and explore structure–activity relationships more efficiently.
Enamine’s participation also adds synthetic chemistry capacity to the collaboration’s “make” step, which is often one of the biggest bottlenecks in early discovery. By pairing generative design with synthetically validated chemical space and rapid synthesis, the team can move through DMTA cycles faster and learn more with each round.
Why this matters?
For this PRMT6 program, speed is only part of the story. The broader goal is to build an open, practical discovery process that can generate novel inhibitor series while making the resulting data available to the wider scientific community.
That combination of transparent collaboration, AI-guided design, and fast synthetic follow-through is what makes this effort distinctive. With Enamine now participating in the project, the collaboration is better positioned to accelerate discovery and expand the search for new therapeutic options for SBMA.